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Searching for ROS1 
Rearrangements 
in Lung Cancer by 
Fluorescent In Situ 
Hybridization
The Importance of  
Probe Design
the INFORM study reports the pro-
longation of OS in EGFR mutation-
positive patients; hence, we strongly 
suggest to conduct a large-scale, ran-
domization phase III trial to compare 
the differences in OS between first-line 
EGFR-TKI treatment followed by che-
motherapy and first-line chemotherapy 
followed by maintenance treatment 
using EGFR-TKIs in patients with 
advanced NSCLC who have EGFR 
mutation-positive tumor.
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To the Editor:
We read with much interest the 
study by Rogers et al. concerning the 
use of fluorescence in situ (FISH), 
chromogenic in situ hybridization, and 
immunohistochemistry (IHC) for the 
detection of ALK and ROS1 rearrange-
ments in lung cancer.1 They concluded 
that FISH versus IHC showed good cor-
relation in the detection of ALK rear-
rangements but weak correlation in the 
detection of ROS1 rearrangements.
We would like to comment on 
this latter conclusion and emphasize 
the importance of FISH “home-made” 
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probe design. ROS1 (position chr6: 
117,609,530-117,747,018 based on the 
UCSC Genome Browser on Human 
February 2009 (GRCh37/hg19) 
Assembly [http://genome.ucsc.edu]) has 
43 exons, of which exons 36 to 41 code for 
the tyrosine kinase domain that is retained 
in all fusion proteins thus far identified. 
Breakpoints in the ROS1 gene cluster in 
introns 31 to 34,2 in a 16kb region (posi-
tion chr6:117,642,538-117,658,284).
Commercially available probes are 
closely located near this breakpoint clus-
ter region (bcr). The ZytoLight SPEC 
ROS1 Dual Color Break Apart Probe 
(ZytoVision, Bremerhaven, Germany) 
is a mixture of two probes, one labeled 
in green and covering the 3′ part of the 
gene, the other labeled in orange and 
covering the 5′ part. Abbott Molecular 
(Des Plaines, IL) commercializes the 
Vysis LSI ROS1 (Cen) SpectrumGreen 
Probe covering the 3′ part of the gene 
that can be used in a mix with the Vysis 
LSI ROS1 (Tel) SpectrumOrange Probe 
that covers the 5′ part of ROS1. In both 
cases, ROS1 fusion with its gene partner 
separates both probes.
FISH “home-made” probes 
are constructed from BAC (Bacterial 
Artificial Chromosome) clones. In 
each construction, one probe is labeled 
in green and the other in orange. Five 
groups, including Rogers et al., have 
reported their results in the literature 
(Fig. 1).
Two groups used the same con-
struct.1,3 They mixed RP11-835I21 
(chr6: 117,844,792-118,035,413) and 
RP11-1036C2 (chr6: 117,408,637-
117,598,872), centromeric and telo-
meric of the ROS1 gene, respectively 
(Fig. 1). Rogers et al. also mentioned an 
additional clone, RP11-378F24, which 
is not referenced in databases and is 
presumably RP11-379F24. Therefore, 
the gap between both probes covers 
246kb and does not cover any part of 
the ROS1 gene.
Two other groups used almost 
identical homemade kits. Takeuchi et 
al. prepared a mix of RP1-179P9 (chr6: 
117,569,584-117,677,843), covering 
exons 25 to 43 and sequences flanking 
the 3′ part of the gene, and RP11-323I17 
(chr6: 117,659,043-117,800,093), cov-
ering sequences flanking the 5′ part and 
the first 31 exons of the gene (Fig. 1).2 
Rikova et al. also used RP1-179P9 as 
the 3′ probe and RP11-323O17 (chr6: 
117,659,115-117,800,072, equiva-
lent to RP11-323I17) and RP1-94G16 
(chr6: 117808698-117909505) as the 5′ 
probe (Fig. 1).4 With these constructs, 
RP1-179P9 would be split by break-
points occurring in the bcr region. 
FIGURE 1.  Positions of the BAC clones and ROS1 gene based on the UCSC Genome Browser on Human February 2009 
(GRCh37/hg19) Assembly (http://genome.ucsc.edu). Colors refer to the different types of construct. Red Rogers et al.1 and 
Bergethon et al.3; blue Takeuchi et al.2; yellow Rikova et al.4; green Davies et al.5 The two vertical lines represent the breakpoint 
cluster region.
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Although the probe at the 3′ end will be 
separated from those at the 5′ end of the 
gene in case of fusion, separation does 
not specifically target the bcr.
Davies et al. designed a cus-
tomized ROS1 break-apart probe 
set made of clones CTD-2314K7 
(chr6: 117,338,338-117,438,446) and 
RP11-59K17 (chr6: 117,448,944-
117,627,275), covering exons 42 
and 43 and sequences flanking the 3′ 
part of the gene, and RP11-623N3 
(chr6: 117,654,640-117,833,020) and 
RP11-117O13 (chr6: 117,830,521-
117,971,596) covering sequences flank-
ing the 5′ part and the first 31 exons and 
a small portion of intron 31 of the gene 
(Fig. 1).5 This construct leaves a 27 kb 
gap in which bcr is located.
These FISH “home-made” probe 
sets differ not only by the BAC clones 
used to build them but also by the dis-
tance between clones, varying from 27 
to 246 kb. In fact, the greater the dis-
tance from bcr, the more likely false 
positives could happen. Indeed, breaks 
could occur outside ROS1 bcr and 
even outside the gene, without fusion 
leading to kinase activation. Also, it 
has been shown that deletion of the 5′ 
region could be associated with a ROS1 
fusion, as it has been reported to happen 
during fusions of other genes such as 
those involving ABL1, MLL.6 In these 
cases, deletion occurs at the breakpoint 
site. Therefore, identifying a deletion of 
RP11-835I21, as used by Rogers et al.1 
and Bergethon et al.,3 does not mean 
that sequences of the 5′ part of ROS1 
were removed.
The diversity in probe design 
could explain, at least partially, the 
discrepancies between IHC and FISH 
results. Home-made probes are a good 
alternative to commercially available 
probes but they have to be designed 
carefully. Interpretation of the results 
requires a good knowledge of the design 
of the probes being used to enable mech-
anisms of the chromosomal and molec-
ular rearrangements to be elucidated.
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In Response:
We thank Uguen et al. for their 
interest in our recently published manu-
script titled Comparison of methods 
in the detection of ALK and ROS1 
rearrangements in lung cancer.1 We 
acknowledge their concerns regard-
ing the use of homemade fluorescent 
in situ  hybridization (FISH) probes 
and the importance of their design. At 
the time that the study was conducted 
there were no commercial ROS1 FISH 
probes available therefore we used the 
home-made ROS1 FISH probe that was 
kindly gifted to us from Translational 
Research Laboratory, Massachusetts 
General Hospital and previously uti-
lized in the study by Bergethon et al.2 
Subsequently, when commercial ROS1 
FISH probes became available, spe-
cifically the Cytocell Aquarius ROS1 
Breakapart FISH Probe (Cambridge, 
UK) and Vysis 6q22 ROS1 Break Apart 
FISH Probe Kit (Des Plaines, IL), we 
repeated the cases which were consid-
ered ROS1 positive or atypical. The 
Cytocell Aquarius ROS1 Breakapart 
FISH Probe showed the same results as 
with the homemade ROS1 FISH probe. 
However, the Vysis 6q22 ROS1 Break 
Apart FISH Probe Kit showed the same 
results for the positive case which con-
tained the break and the atypical case 
(loss of 3′ end) but the two other cases 
defined by loss of the 5′ end using the 
home-made ROS1 FISH probe were 
negative by the Vysis 6q22 ROS1 Break 
Apart FISH Probe Kit. This as antici-
pated and highlighted by Uguen et al. 
show there are differences in FISH sig-
nal patterns that is dependent on probe 
design.
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